Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry in China, indicating an expectation of returns exceeding the market benchmark by more than 5% [5]. Core Insights - Tirzepatide has been crowned the "King of Drugs," with annual sales reaching $36.507 billion in 2025, representing a 122% increase. It is expected to maintain its leading position for several years. Other notable drugs include Pembrolizumab with $31.7 billion in sales (+7%) and Semaglutide with approximately $34.606 billion (+18%) [9]. - The weight loss market is becoming a strategic focus for multinational corporations (MNCs), with significant investments and mergers and acquisitions (M&A) occurring in this sector. Major players are prioritizing weight loss in their strategies, with various drugs expected to enter clinical trials and receive approvals in 2026 [9]. - The demand for weight loss solutions is driving ongoing business development (BD) activities, with recent agreements indicating a robust pipeline for future innovations in this area [9]. - The commercial value of weight loss drugs is anticipated to be rapidly released, with MNCs viewing this sector as a core strategic area, leading to continued BD opportunities in oral small molecules, long-acting GLP-1s, and small nucleic acids [9]. Summary by Sections Investment Recommendations and Targets - Recommended stocks include: - Genscript Biotech Corporation (01672, Buy) - Hengrui Medicine (600276, Buy) - Zhongsheng Pharmaceutical (002317, Buy) - Yuyuan Pharmaceutical (688658, Buy) - Shijiazhuang Pharmaceutical Group (01093, Not Rated) - Sunshine Novo Nordisk (688621, Buy) [9].

Core Viewpoint - Heng Rui Medicine (01276) has seen its stock price increase by over 3%, currently trading at HKD 68.75 with a transaction volume of HKD 71.27 million, following the acceptance of two drug application submissions by the National Medical Products Administration (NMPA) [1][1]. Group 1: Drug Application Acceptance - The company's subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., received an acceptance notice from the NMPA for the drug application of HR20013, an injectable formulation of Phosphorlorapitant Palonosetron, aimed at preventing nausea and vomiting induced by moderately emetogenic chemotherapy [1][1]. - The application for HR20013 is based on a multicenter, randomized, double-blind, positive-controlled Phase III clinical trial (HR20013-302) evaluating its efficacy and safety [1][1]. Group 2: Innovative Drug Submission - Heng Rui Medicine and its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., also received an acceptance notice from the NMPA for a new indication of the innovative drug, injectable Camrelizumab, in combination with Apatinib Mesylate tablets [1][1]. - This application is based on a randomized controlled, open-label, multicenter Phase III clinical trial (SHR-1210-III-336 study) comparing the efficacy and safety of Camrelizumab and Apatinib combined with TACE versus TACE alone in patients with unresectable hepatocellular carcinoma [1][1].

每经AI快讯，恒瑞医药(01276.HK)涨超3%，截至发稿，涨3%，报68.75港元，成交额7126.63万港元。 ...

Core Viewpoint - Heng Rui Medicine (600276) has seen its stock price increase by over 3%, currently trading at 68.75 HKD with a transaction volume of 71.27 million HKD, following the acceptance of two drug application submissions by the National Medical Products Administration (NMPA) [1] Group 1: Drug Approvals - The company's subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., received an acceptance notice from the NMPA for the marketing authorization application of HR20013, an injectable drug for preventing nausea and vomiting caused by moderately emetogenic anticancer drugs, based on a Phase III clinical trial [1] - Heng Rui Medicine and its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., also received an acceptance notice for the marketing authorization application of a new indication for the innovative drug SHR-1210 (injectable carrelizumab) in combination with apatinib, based on a Phase III clinical trial comparing the efficacy and safety of the combination treatment against TACE alone for patients with unresectable hepatocellular carcinoma [1]

Core Viewpoint - Heng Rui Medicine (01276) has seen its stock price increase by over 3%, currently trading at HKD 68.75, with a transaction volume of HKD 71.27 million [1] Group 1: Regulatory Approvals - The company's subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration (NMPA) for the marketing authorization application of HR20013, an injectable drug for preventing nausea and vomiting caused by moderately emetogenic anticancer drugs [1] - The application for HR20013 is based on a multicenter, randomized, double-blind, positive-controlled Phase III clinical trial (HR20013-302) evaluating its efficacy and safety [1] Group 2: New Indications for Existing Drugs - Heng Rui Medicine and its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., have also received a "Notice of Acceptance" from the NMPA for the marketing authorization application of a new indication for the innovative drug, SHR-1210 (injectable carrelizumab) in combination with apatinib mesylate tablets [1] - This application is based on a randomized controlled, open-label, multicenter Phase III clinical trial (SHR-1210-III-336 study) comparing the efficacy and safety of carrelizumab and apatinib combined with TACE versus TACE alone in patients with unresectable hepatocellular carcinoma [1]

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index (HSSCPB) decreased by 1.40% as of February 5, 2026, with mixed performance among constituent stocks [1] - Notable gainers included Nocera Healthcare up 3.87%, Four Seasons Pharmaceutical up 3.14%, and Heng Rui Medicine up 2.77%, while MIRXES-B led the decline down 9.12% [1] - The Hong Kong Innovative Drug ETF (520690) fell by 1.20%, with a latest price of 0.82 yuan, but showed a 2.97% increase over the past month as of February 4, 2026 [1] Group 2 - As of January 31, 2026, 283 pharmaceutical stocks disclosed their 2025 earnings forecasts, with 160 stocks expected to see year-on-year profit growth, highlighting a positive trend in the innovative drug sector [2] - Sino Medical emerged as the "profit growth king" in A-shares with a forecasted increase of over 32 times, while WuXi AppTec is expected to achieve a record net profit of 19.151 billion yuan [2] - The demand for weight loss drugs remains strong, with Eli Lilly reporting a 43% year-on-year revenue increase to $19.29 billion in Q4, exceeding market expectations [2] Group 3 - Donghai Securities indicated that the innovative drug sector is entering a phase of accelerated profit realization, driven by rapid commercialization of products and business development collaborations [3] - The performance of the innovative drug sector validates the effectiveness of the domestic innovative drug business model, with core products supported by medical insurance driving growth [3] - The Hong Kong Innovative Drug ETF has seen continuous net inflows, totaling 16.3621 million yuan over three days, with a maximum single-day inflow of 8.9766 million yuan [3]

Group 1 - The stock market style may be changing, with a notable adjustment in US tech stocks, including Oracle's price dropping nearly 60% from its peak and SNDK experiencing a significant decline [1] - A-shares may see a shift in style, with banks and dividend stocks potentially outperforming, leading to a focus on quality banks such as Jiangsu Bank, Nanjing Bank, Hangzhou Bank, Ningbo Bank, and China Merchants Bank for potential gains [1] - As of February 4, 2026, the Shanghai 180 Index (000010) rose by 1.01%, with component stocks like JinkoSolar up 20.00%, Yanzhou Coal Mining up 10.01%, and China Shenhua Energy also seeing gains [1] Group 2 - The Shanghai 180 ETF index fund (530280) has seen a net value increase of 14.84% over the past six months, with a maximum monthly return of 9.13% since inception [2] - The fund has a historical average monthly return of 3.08% and a 100% probability of profitability over one year, with a Sharpe ratio of 2.08 as of January 30, 2026 [2] - The fund's maximum drawdown this year is 4.28%, with a management fee of 0.15% and a custody fee of 0.05% [2] Group 3 - As of January 30, 2026, the top ten weighted stocks in the Shanghai 180 Index include Zijin Mining, Kweichow Moutai, China Ping An, and others, collectively accounting for 24.85% of the index [3] - The individual weightings of these stocks vary, with Kweichow Moutai at 4.22% and China Ping An at 2.87% [4]

Strategy Research - The macroeconomic landscape shows a divergence in performance, with strong demand for technology hardware driven by AI infrastructure investment, while chemical prices remain robust due to supply constraints [2][3] - High-end liquor prices are stabilizing, indicating some recovery in consumer spending, although the sustainability of this trend remains uncertain [3][4] Food and Beverage Research - The company Sobo Protein is expected to maintain rapid profit growth in Q4 2025, with projected net profit for 2025 ranging from 178 to 191 million yuan, reflecting a year-on-year increase of 46.89% to 57.62% [8][36] - The company is focusing on high-end manufacturing and energy optimization, which is expected to enhance profitability [37] Automotive Research - The Robotaxi market in China is projected to reach a value of 50 billion yuan, with hardware cost reductions and software iterations driving demand [11][29] - The commercial viability of Robotaxi is approaching a critical point, with both L2 and L4 participants accelerating market penetration [11][29] Consumer Sector - The price of high-end liquor, such as Moutai, has increased by 3.9% for original and 3.0% for bulk, likely due to pre-holiday gifting demand [4][16] - The real estate market remains weak, with significant declines in transaction volumes across major cities, although policies to stabilize the market are being implemented [4][16] Technology and Manufacturing - The price of DRAM storage has shown signs of stabilization, with a slight decrease in DDR4 prices and a slight increase in DDR5 prices, while overall prices remain high [5][17] - Chemical prices continue to be strong, with PX prices increasing by 5.2% [5][17] Logistics and Transportation - Passenger transport demand remains stable ahead of the holiday season, with a slight increase in logistics demand reflected in highway and rail freight volumes [18] - Shipping rates have shown mixed trends, with domestic port throughput increasing, indicating a potential recovery in export activity [18] Industry Tracking: Machinery - The company Hangzhou Steam Turbine has signed its first commercial contract for a self-developed gas turbine, marking a significant step towards industrial application [19][20] - The company is also advancing its "B to A" strategy to enhance financing channels for high-investment R&D projects [21] Industry Research: Pharmaceuticals - The total market value of publicly held pharmaceutical stocks decreased from 397.7 billion to 316.1 billion yuan, indicating a decline in investor confidence [23][24] - The chemical preparation sector remains the largest segment within pharmaceutical holdings, accounting for 37.5% of total holdings [23] Industry Research: Information Technology - The median profit growth for computer companies is significantly higher than revenue growth, indicating a trend of improving profitability despite stagnant sales [25][26] - A notable number of companies are experiencing significant profit declines, highlighting a polarized performance within the sector [26][28]

Core Insights - Novo Nordisk reported a revenue of 309.06 billion Danish Krone (approximately 48.9 billion USD) for 2025, marking a 6% year-on-year growth, with a net profit of 102.43 billion Danish Krone (approximately 16.2 billion USD), a 1% increase [1] - The drug semaglutide, a key product, generated sales of 36.1 billion USD, showing a growth of over 10% [1] - The competitive landscape in the diabetes and obesity treatment market is intensifying, with policy pressures affecting high-priced innovative drugs [1][4] Financial Performance - Novo Nordisk's total sales for semaglutide reached 228.29 billion Danish Krone (approximately 36.1 billion USD) [3] - The sales breakdown includes Ozempic (127.09 billion Danish Krone or 20.1 billion USD), Wegovy (79.11 billion Danish Krone or 12.5 billion USD), and oral semaglutide (22.09 billion Danish Krone or 3.5 billion USD) [3] - In China, Novo Nordisk's revenue was 18.66 billion Danish Krone (approximately 2.83 billion USD) [3] Market Dynamics - The GLP-1 market is currently dominated by Novo Nordisk and Eli Lilly, with combined revenues nearing 50 billion USD in 2024 [5] - Semaglutide's sales surpassed Merck's Keytruda, which reported sales of 31.68 billion USD [5] - Eli Lilly's tirzepatide is rapidly closing the sales gap with semaglutide, indicating a competitive shift [1][5] Competitive Landscape - The competition is evolving from product sales to comprehensive strategies, including clinical efficacy and pricing [5][7] - A recent study showed that semaglutide reduced the risk of major adverse cardiovascular events by 29% compared to tirzepatide [6] - The GLP-1 market is transitioning from a "blue ocean" to a "red ocean" with increasing competition and innovation opportunities [7] Strategic Initiatives - Novo Nordisk is investing in direct patient outreach programs and partnerships with telehealth providers to enhance market access [8] - The company has implemented cost-saving measures, including a significant workforce reduction of approximately 9,000 employees globally [8][9] - Novo Nordisk's new pricing strategies aim to improve patient affordability and market competitiveness [8] Future Outlook - The expiration of semaglutide's core patent in March 2026 poses a risk of market share erosion due to the entry of generic competitors [4] - The company is focusing on expanding its product pipeline and exploring new indications to sustain growth [9][10] - The ongoing competition between semaglutide and tirzepatide will shape the future dynamics of the GLP-1 market [10]

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical industry, indicating a positive outlook based on ongoing technological innovation and demand growth [5][6]. Core Insights - The total market value of pharmaceutical stocks held by public funds decreased from 397.7 billion to 316.1 billion yuan, reflecting a decline of 2.58% from Q3 2025 to Q4 2025. The proportion of pharmaceutical stocks in all public fund holdings fell to 7.95%, down 2.58 percentage points from the previous quarter [6][9]. - The highest proportion of holdings in the pharmaceutical sector is in chemical preparations, other biological products, and medical research outsourcing, which accounted for 37.5%, 20.9%, and 16.4% of the total holdings, respectively [6][13]. - The top five pharmaceutical stocks by market value held by public funds in Q4 2025 were: Heng Rui Medicine (32 billion), WuXi AppTec (30.6 billion), Innovent Biologics (16.7 billion), Mindray Medical (15.2 billion), and CanSino Biologics (10.8 billion) [6][24]. Summary by Sections 1. Pharmaceutical Holdings Proportion - The proportion of pharmaceutical stocks held by public funds decreased to 7.95% in Q4 2025, down from Q3 2025, with a notable decline in non-pharmaceutical public fund holdings [9][10]. 2. Market Value of Pharmaceutical Sub-sectors - In Q4 2025, the market value of pharmaceutical sub-sectors held by public funds was as follows: 1. Chemical preparations: 118.6 billion yuan (37.5%) 2. Other biological products: 66 billion yuan (20.1%) 3. Medical research outsourcing: 51.7 billion yuan (16.4%) 4. Medical devices: 33.3 billion yuan (10.5%) 5. Medical consumables: 9.8 billion yuan (3.1%) [13][12]. 3. Public Fund Heavy Holdings - The number of public funds holding the top five pharmaceutical stocks in Q4 2025 was as follows: Heng Rui Medicine (507 funds), WuXi AppTec (448 funds), Mindray Medical (204 funds), Innovent Biologics (202 funds), and BeiGene (162 funds) [17][21]. - The market value growth of public fund heavy holdings in Q4 2025 saw significant increases for Heng Rui Medicine (+20.1 billion), WuXi AppTec (+5.7 billion), China National Pharmaceutical Group (+5 billion), Yingke Medical (+2.2 billion), and Yuyue Medical (+1.8 billion) [28].